The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | Advancing our understanding of resistance mechanisms to anti-BCMA therapies in multiple myeloma
In this video, Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses recent advances in understanding resistance mechanisms in patients with multiple myeloma who progress on anti-BCMA therapies. Dr Raje highlights that studies are exploring the role of antigen loss, sequencing, and microenvironmental factors, and notes that while some resistance mechanisms are well understood, others are still being studied. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
